Latest Health News

Proteomics International’s subsidiary OxiDx has unveiled a pioneering test that detects muscle damage in thoroughbred racehorses, promising to transform recovery management in the racing industry. The test’s commercial launch is slated for the second half of 2025.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

InteliCare has launched a three-month trial of its AI-powered platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy with a leading aged care provider.

TALi Digital has completed a modest capital raise through a 1-for-6 entitlement offer, coinciding with its strategic acquisition of You Can Do It! Education, signaling a push into social-emotional learning.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.

Race Oncology has secured key ethics approvals to launch its Phase 1 RC220 trial at two major Hong Kong hospitals, marking a strategic expansion beyond Australia to accelerate patient recruitment and explore cardioprotective benefits.

Artrya Limited has secured a five-year, US$0.6 million contract with Tanner Health, marking its inaugural commercial revenue in the U.S. market for its AI-powered Salix Coronary Anatomy platform.

Mach7 Technologies maintains its FY25 revenue growth guidance with strong recurring revenue gains, despite a modest shortfall in contracted annual recurring revenue. The company also advances its share buyback program, signaling confidence in its financial position.

Aurelia Metals has successfully met its FY25 production guidance across all key metals while strengthening its cash position to A$110 million, setting the stage for upcoming growth projects including the Great Cobar development.

InteliCare Holdings has raised $1 million through a structured financing deal to extend its cash runway and scale its AI-driven healthcare platform across aged care and disability sectors.

Telix Pharmaceuticals has achieved a key milestone with its next-generation prostate cancer imaging agent, Gozellix, receiving a permanent HCPCS code from U.S. Medicare. This paves the way for broader reimbursement and market adoption starting October 2025.

Anatara Lifesciences has strengthened its intellectual property portfolio with a Japanese patent for its GaRP gastrointestinal health product, while progressing pre-clinical studies in its Anti-Obesity Project. The company also confirmed registration of its R&D Tax Incentive application for 2024-2025.